Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Carcinoma In Situ Clear all
Completed No phase listed Observational

Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial

NCT00666913
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
informational intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Sep 30, 2026, 2:45 AM EDT
Recruiting Phase 2 Interventional

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

NCT05941520
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors

NCT04999826
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 30, 2026, 2:45 AM EDT
Active, not recruiting Early Phase 1 Interventional

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

NCT02872025
View directory record Official record
Conditions
Carcinoma, Intraductal, Noninfiltrating
Interventions
Pembrolizumab, Intralesional mRNA 2752
Drug · Biological
Lead sponsor
Laura Esserman
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 30, 2026, 2:45 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

NCT01349322
View directory record Official record
Conditions
Breast Cancer
Interventions
Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
386
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients

NCT02018419
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
AlloStim, Cryoablation
Biological · Procedure
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Not applicable Interventional

THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence

NCT06388304
View directory record Official record
Conditions
Breast Cancer, DCIS
Interventions
THRIVE Online PAT Program
Behavioral
Lead sponsor
Joanna Arch
Other
Eligibility
21 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery

NCT02391194
View directory record Official record
Conditions
Breast Cancer
Interventions
AVB-620
Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
La Jolla, California • San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 30, 2026, 2:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Identifying and Caring for Individuals With Inherited Cancer Syndrome

NCT04494945
View directory record Official record
Conditions
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphoid System Neoplasm, Hereditary Neoplastic Syndrome, Lynch Syndrome, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Genetic Counseling, Genetic Testing, Survey Administration
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Active, not recruiting Phase 1 Interventional

Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer

NCT05340673
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Agent Affecting Integumentary System, Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Completed No phase listed Observational

Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

NCT06234488
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Adenocarcinoma, Breast Cancer Stage, Breast Cancer Stage IV, Breast Cancer Invasive, Breast Cancer in Situ
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Effects of Diet and Exercise on Ductal Carcinoma in Situ

NCT02224807
View directory record Official record
Conditions
Ductal Carcinoma In Situ, Breast Cancer
Interventions
Active Comparator: Progressive Resistance Training (PRT) and a healthy diet, Experimental: PRT and a healthy diet, plus weight loss
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors

NCT04290897
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Anhydrous Enol-oxaloacetate, Questionnaire Administration
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 30, 2026, 2:45 AM EDT
Completed No phase listed Observational

Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease

NCT00898508
View directory record Official record
Conditions
Breast Cancer
Interventions
gene expression analysis, mutation analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, medical chart review, quality-of-life assessment
Genetic · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
20 Years and older · Female only
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
3
States / cities
Beverly Hills, California • Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

NCT01849250
View directory record Official record
Conditions
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Docosahexaenoic Acid, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 30, 2026, 2:45 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

NCT01372618
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
SOM 230 / Pasireotide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

NCT01194440
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
letrozole, zoledronic acid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Sep 30, 2026, 2:45 AM EDT
Recruiting No phase listed Observational

Prospective Breast Cancer Biospecimen Collection

NCT04074720
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer, Carcinoma in Situ of the Breast
Interventions
Tissue Sample collection, Blood Sample Collection, Rectal Swab
Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Not applicable Interventional

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

NCT01097278
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
cholecalciferol, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 50 Years · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
360
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ

NCT00586326
View directory record Official record
Conditions
DCIS
Interventions
MammoSite Radiation Therapy System
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
45 Years and older · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
12
States / cities
Phoenix, Arizona • Inglewood, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

NCT02636582
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ
Interventions
Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure
Other · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00388115
View directory record Official record
Conditions
Breast Cancer
Interventions
conventional surgery, neoadjuvant therapy, radiofrequency ablation
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

NCT03323658
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Bexarotene, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 30, 2026, 2:45 AM EDT